Vítor Ennes-Vidal

Dr. Vítor Ennes-Vidal

Oswaldo Cruz Institute
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2016 in Parasitology
Verified
Journal Article
Open access
PDF file
Vítor Ennes-VidalVítor Ennes-Vidal
Vítor Ennes-Vidal
RMRubem Figueiredo Sadock Menna-Barreto
Rubem Figueiredo Sadock Menna-Barreto
MBMarta Helena Branquinha
Marta Helena Branquinha
ASAndré Luis Souza DOS Santos
André Luis Souza DOS Santos
CDClaudia M d’Avila-Levy
Claudia M d’Avila-Levy
SUMMARY: Leishmaniasis is a neglected disease, which needs improvements in drug development, mainly due to the toxicity, parasite resistance and low compliance of patients to treatment. Therefore, the development of new chemotherapeutic compounds is an urgent need. This opinion article will briefly highlight the feasible use of calpain inhibitors as leading compounds to search for new therapeutic options to treat leishmaniasis. The milestone of this approach is to take advantage on the myriad of inhibitors developed against calpains, some of which are in advanced clinical trials. The deregulated activity of these enzymes is associated with several pathologies, such as strokes, diabetes and Parkinson's disease, to name a few. InLeishmania, calpain upregulation has been associated to drug resistance and virulence. Whereas the difficulties in developing new drugs for neglected diseases are more economical than biotechnological, repurposing approach with compounds already approved for clinical use by the regulatory agencies can be an interesting shortcut to a successful chemotherapeutic treatment for leishmaniasis.

16 September 2013 in Malaria Journal
Verified
Journal Article
Open access
PDF file
EREvelyn Kp Riccio
Evelyn Kp Riccio
PTPaulo Renato Totino
Paulo Renato Totino
LPLilian Rose Pratt-Riccio
Lilian Rose Pratt-Riccio
Vítor Ennes-VidalVítor Ennes-Vidal
Vítor Ennes-Vidal
ISIrene Soares
Irene Soares
MCMaria de Fátima Ferreira da Cruz
Maria de Fátima Ferreira da Cruz
Plasmodium vivax merozoite surface protein-1 (MSP-1) is an antigen considered to be one of the leading malaria vaccine candidates. PvMSP-1 is highly immunogenic and evidences suggest that it is target for protective immunity against asexual blood stages of malaria parasites. Thus, this study aims to evaluate the acquired cellular and antibody immune responses against PvMSP-1 in individuals naturally exposed to malaria infections in a malaria-endemic area in the north-eastern Amazon region of Brazil.

1 February 2021 in Cells
Verified
Journal Article
Open access
PDF file
Vítor Ennes-VidalVítor Ennes-Vidal
Vítor Ennes-Vidal
Marta Helena BranquinhaMarta Helena Branquinha
Marta Helena Branquinha
André Luis SantosAndré Luis Santos
André Luis Santos
CDClaudia M d’Avila-Levy
Claudia M d’Avila-Levy
Calpains are calcium-dependent cysteine peptidases that were originally described in mammals and, thereafter, their homologues were identified in almost all known living organisms. The deregulated activity of these peptidases is associated with several pathologies and, consequently, huge efforts have been made to identify selective inhibitors. Trypanosomatids, responsible for life-threatening human diseases, possess a large and diverse family of calpain sequences in their genomes. Considering that the current therapy to treat trypanosomatid diseases is limited to a handful of drugs that suffer from unacceptable toxicity, tough administration routes, like parenteral, and increasing treatment failures, a repurposed approach with calpain inhibitors could be a shortcut to successful chemotherapy. However, there is a general lack of knowledge about calpain functions in these parasites and, currently, the proteolytic activity of these proteins is still an open question. Here, we highlight the current research and perspectives on trypanosomatid calpains, overview calpain description in these organisms, and explore the potential of targeting the calpain system as a therapeutic strategy. This review gathers the current knowledge about this fascinating family of peptidases as well as insights into the puzzle: are we unable to measure calpain activity in trypanosomatids, or are the functions of these proteins devoid of proteolytic activity in these parasites?

1 December 2017 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
ABAna Cristina Souza Bombaça
Ana Cristina Souza Bombaça
FDFelipe de Almeida Dias
Felipe de Almeida Dias
Vítor Ennes-VidalVítor Ennes-Vidal
Vítor Ennes-Vidal
AGAline dos Santos Garcia-Gomes
Aline dos Santos Garcia-Gomes
MSMarcos Henrique Ferreira Sorgine
Marcos Henrique Ferreira Sorgine
Rubem Menna-BarretoRubem Menna-Barreto
Rubem Menna-Barreto

Verified
Journal Article
Open access
PDF file
Vítor Ennes-VidalVítor Ennes-Vidal
Vítor Ennes-Vidal
DADeborah Antunes
Deborah Antunes
EPEster Poláková
Ester Poláková
Vyacheslav YurchenkoVyacheslav Yurchenko
Vyacheslav Yurchenko
SSSimone Santiago
Simone Santiago
CDClaudia M. D’avila-Levy
Claudia M. D’avila-Levy
Leishmania tarentolae is a non-pathogenic trypanosomatid isolated from lizards widely used for heterologous protein expression and extensively studied to understand the pathogenic mechanisms of leishmaniasis. The repertoire of leishmanolysin genes was reported to be expanded in L. tarentolae genome, but no proteolytic activity was detected. Here, we analyzed L. tarentolae leishmanolysin proteins from the genome to the structural levels and evaluated the enzymatic activity of the wild-type and overexpressing mutants of leishmanolysin. A total of 61 leishmanolysin sequences were retrieved from the L. tarentolae genome. Five of them were selected for phylogenetic analysis, and for three of them, we built 3D models based on the crystallographic structure of L. major ortholog. Molecular dynamics simulations of these models disclosed a less negative electrostatic potential compared to the template. Subsequently, L. major LmjF.10.0460 and L. tarentolae LtaP10.0650 leishmanolysins were cloned in a pLEXSY expression system into L. tarentolae. Proteins from the wild-type and the overexpressing parasites were submitted to enzymatic analysis. Our results revealed that L. tarentolae leishmanolysins harbor a weak enzymatic activity about three times less abundant than L. major leishmanolysin. Our findings strongly suggest that the less negative electrostatic potential of L. tarentolae leishmanolysin can be the reason for the reduced proteolytic activity detected in this parasite.

1 January 2022 in Memórias do Instituto Oswaldo Cruz
Verified
Journal Article
Open access
Vítor Ennes-VidalVítor Ennes-Vidal
Vítor Ennes-Vidal
ASAndré Luis Souza dos Santos
André Luis Souza dos Santos
MBMarta Helena Branquinha
Marta Helena Branquinha
CDClaudia Masini D’aVila-Levy
Claudia Masini D’aVila-Levy
The treatment for tropical neglected diseases, such as Chagas disease (CD) and leishmaniasis, is extremely limited to a handful of drugs that suffer from unacceptable toxicity, tough administration routes, like parenteral, and increasing treatment failures due to the parasite resistance. Consequently, there is urgency for the development of new therapeutic options to treat such diseases. Since peptidases from these parasites are responsible for crucial functions in their biology, these molecules have been explored as alternative targets. In this context, a myriad of proteolytic inhibitors has been developed against calcium-dependent cysteine-type peptidases, collectively called calpains, which are implicated in several human pathophysiological diseases. These molecules are highly expanded in the genome of trypanosomatids and they have been reported participating in several parasite biological processes. In the present perspective, we discuss our almost two decades of experience employing the calpain inhibitors as an interesting shortcut to a possible repurpose strategy to treat CD and leishmaniasis.